GnRHR

GnRHR is the class A GPCR that translates pulsatile hypothalamic GnRH signals into pituitary LH and FSH secretion - the master switch for the reproductive axis. It is the target for the largest class of approved peptide hormonal therapies: GnRH agonist analogs that paradoxically suppress gonadal steroid production through receptor desensitization, and GnRH antagonists that block the receptor directly. Approved agents cover prostate cancer, endometriosis, uterine fibroids, precocious puberty, and IVF protocols. Every scaffold in reproductive medicine, oncology hormone suppression, or hypothalamic neuropeptide pharmacology routes through this card.

GnRHR (chromosome 4q13.2-13.3, 328 aa) is uniquely truncated among mammalian class A GPCRs: it lacks a cytoplasmic C-terminal tail entirely, which dramatically slows β-arrestin recruitment, reduces receptor internalization, and prolongs downstream signaling. Primary coupling is Gq/11 → PLC-β → IP3/DAG → intracellular Ca²⁺ and PKC → MAPK/ERK → LH/FSH gene expression and gonadotropin exocytosis. Secondary: Gs → cAMP in some contexts. Key binding contacts are Asp^2.61(98) and Glu^2.53(90) (anchoring GnRH His¹ and Arg⁸), and Tyr^6.58(290) (stacking Trp³). Pulsatile GnRH (every 60–90 min) drives LH/FSH release; continuous stimulation desensitizes the receptor and collapses LH/FSH - the pharmacological basis of agonist-mediated medical castration. Inactivating GNRHR mutations (Q106R, R262Q most common) cause normosmic congenital hypogonadotropic hypogonadism (nCHH), accounting for ~10–40% of GnRHR-linked nCHH cases. Many nCHH-associated mutants are misfolded but retain intrinsic function - they are rescuable by pharmacoperone small molecules that act as molecular chaperones.

Approved GnRH agonist analogs (all DPP-4-resistant through D-amino acid or Aib substitutions): leuprolide (daily, depot, or microsphere SC), goserelin (SC implant), triptorelin (depot IM), buserelin, histrelin (SC implant for precocious puberty) - all used for prostate cancer, endometriosis, precocious puberty, and breast cancer. Approved GnRH antagonists: cetrorelix and ganirelix (SC, IVF ovarian hyperstimulation prevention), degarelix (SC depot, prostate cancer), elagolix (oral, endometriosis/uterine fibroids), relugolix (oral, prostate cancer and uterine fibroids). For peptide research, the tractable recipes are: D-amino acid and Aib scanning of native GnRH to define the minimal pharmacophore for agonist vs. antagonist activity; pharmacoperone peptides that rescue GnRHR nCHH mutants as a molecular chaperone strategy; GnRH analogs with C-terminal PEGylation or fatty acid conjugation for extended duration; and GnRH(1-5) fragments that act through non-GnRHR pathways to modulate dopaminergic circuits as neuromodulatory peptide scaffolds.